Abstract
Purpose: Tanezumab, a monoclonal antibody against nerve growth factor, is in clinical development for the treatment of moderate to severe chronic pain of osteoarthritis (OA). A randomized, double-blind, double-dummy, active-controlled phase 3 study investigated the long-term safety and efficacy of subcutaneous (SC) tanezumab vs oral nonsteroidal anti-inflammatory drugs (NSAIDs) in patients with hip or knee OA (NCT02528188). Here we examine the efficacy response after 16 weeks of tanezumab or NSAID across different patient subgroups.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
